p53-Y220C,SNAr

Theresa Klett1, Jason Stahlecker1, Martin Schwer1

  • 1Laboratory for Molecular Design & Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, 72076, Germany.

概括

研究人员开发了新的pyrazine衍生物来稳定常见的与癌症相关的p53-Y220C突变. 化合物SN006/7-8显著增强了热稳定性,为p53突变癌症提供了一个有前途的治疗途径.